Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014

Epidemiology and Infection

Volumn 144, Issue 11, 2016, Pages 2317-2328

  Sullivan, S G ^a,b,c,d   Carville, K S ^a   Chilver, M ^c   Fielding, J E ^a,d,e   Grant, K A ^a   Kelly, H ^a,d,e   Levy, A ^f,g   Stocks, N P ^c   Tempone, S S ^f   Regan, A K ^g,h  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e The Australian National University   (Australia)

^f PATHWEST LABORATORY MEDICINE   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h DEPARTMENT OF HEALTH   (Australia)

Author keywords

Influenza; influenza season; influenza vaccine; influenza like illness; vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; GENERAL PRACTITIONER; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; THROAT CULTURE; VIRUS STRAIN; ADOLESCENT; IMMUNOLOGY; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEASON; SENTINEL SURVEILLANCE; STATISTICAL MODEL; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEASONS; SENTINEL SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 84964662021     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268816000819     Document Type: Article

References (64)

1. Kelly H, et al. Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS ONE 2009; 4: e5079.
2. Sullivan SG, et al. Influenza vaccine effectiveness in Australia: results from the Australian Sentinel Practices Research Network. Medical Journal of Australia 2014; 201: 109-111.
3. Levy A, et al. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. Vaccine 2014; 32: 6312-6318.
4. Turner N, et al. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. Eurosurveillance 2014; 19.
5. McAnerney JM, et al. Effectiveness and knowledge, attitudes and practises of seasonal influenza vaccine in primary health care settings in South Africa, 2010-2013. Influenza and Other Respiratory Viruses 2015; 9: 143-150.
6. Anon. Surveillance systems reported in CDI, 2011. Communicable Diseases Intelligence Quarterly Report 2011; 35: 55-59.
7. Parrella A, et al. ASPREN surveillance system for influenza-like illness-a comparison with FluTracking and the National Notifiable Diseases Surveillance System. Australian Family Physician 2009; 38: 932-936.
8. Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine 2013; 31: 4280-4283.
9. Sullivan SG, Kelly H. Late season interim estimates of influenza vaccine effectiveness reliably predict end of season estimates in Victoria, Australia, 2007-2012. Eurosurveillance 2013; 18: pii = 20605.
10. Sullivan SG, et al. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. Journal of Medical Virology 2014; 86: 1017-1025.
11. Carville KS, et al. Understanding influenza vaccine protection in the community: An assessment of the 2013 influenza season in Victoria, Australia. Vaccine 2015; 33: 341-345.
12. Widdowson MA, Monto AS. Epidemiology of influenza. In: Wenster RG, et al., eds. Textbook of Influenza, 2nd edn. Chichester, West Sussex, UK: Wiley Blackwell, 2013, pp. 254-255.
13. Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Current Opinions in Immunology 2014; 29: 38-42.
14. Sullivan SG, Feng S, Cowling BJ. Potential of the testnegative design for measuring influenza vaccine effectiveness: A systematic review. Expert Review of Vaccines 2014; 13: 1571-1591.
15. Smith-Warner SA, et al. Methods for pooling results of epidemiologic studies: The Pooling Project of Prospective Studies of Diet and Cancer. American Journal of Epidemiology 2006; 163: 1053-1064.
16. Blettner M, Sauerbrei W. Influence of model-building strategies on the results of a case-control study. Statistics in Medicine 1993; 12: 1325-1338.
17. Kissling E, et al. 'I-MOVE' towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euroaurveillance 2009; 14.
18. Skowronski DM, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. Journal of Infectious Diseases 2014; 210: 126-137.
19. Ohmit SE, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clinical Infectious Diseases 2014; 58: 319-327.
20. Australian Government Department of Health and Ageing. Part 4: Vaccine-preventable diseases. In: The Australian Immunisation Handbook, 10th edn. Canberra: National Health and Medical Research Council, 2015, pp. 251-256.
21. Hobson D, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene 1972; 70: 767-777.
22. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31: 2165-2168.
23. Orenstein EW, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology 2007; 36: 623-631.
24. Skowronski D, et al. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Canada Communicable Disease Report 2005; 31: 181-191.
25. Harris R, et al. metan: fixed-and random-effects meta-analysis. Stata Journal 2008; 8: 3-28.
26. Greenland S. Invited commentary: A critical look at some popular meta-analytic methods. American Journal of Epidemiology 1994; 140: 290-296.
27. Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology 1993; 4: 295-302.
28. Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. International Journal of Epidemiology 2007; 36: 195-202.
29. Kissling E, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/ subtypes circulating: The I-MOVE multicentre casecontrol study, influenza season 2012/13. Eurosurveillance 2014; 19.
30. Skowronski DM, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the eggadapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE 2014; 9: e92153.
31. Pierse N, et al. Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, NewZealand 2014. Vaccine 2016; 34: 503-509.
32. Lytras T, et al. Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: A test-negative study. Vaccine 2015; 33: 367-373.
33. Andrews N, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/ 13 end of season results. Eurosurveillance 2014; 19: 5-13.
34. Yang P, et al. Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China. Vaccine 2014; 32: 5285-5289.
35. Jimenez-Jorge S, et al. Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014. Vaccine 2015; 33: 3276-3280.
36. Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Eurosurveillance 2013; 18: pii = 20388.
37. Blyth CC, et al. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics 2014; 133: e1218-1225.
38. Kelly HA, et al. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Medical Journal of Australia 2011; 195: 318-320.
39. Ampofo K, et al. Epidemiology, complications, and cost of hospitalization in children with laboratoryconfirmed influenza infection. Pediatrics 2006; 118: 2409-2417.
40. Bhat N, et al. Influenza-associated deaths among children in the United States, 2003-2004. New England Journal of Medicine 2005; 353: 2559-2567.
41. Grijalva CG, et al. Estimating the undetected burden of influenza hospitalizations in children. Epidemiology and Infection 2007; 135: 951-958.
42. Ji W, et al. The epidemiology of hospitalized influenza in children, a two year population-based study in the People's Republic of China. BMC Health Services Research 2010; 10: 82.
43. Poehling KA, et al. The underrecognized burden of influenza in young children. New England Journal of Medicine 2006; 355: 31-40.
44. Jefferson T, et al. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2012; 8: CD004879.
45. Booy R, et al. Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. Medical Journal of Australia 2011; 194: 19-23.
46. Hancock K, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. New England Journal of Medicine 2009; 361: 1945-1952.
47. Miller E, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010; 375: 1100-1108.
48. Hay AJ, et al. The evolution of human influenza viruses. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2001; 356: 1861-1870.
49. Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. Journal of Infectious Diseases 2009; 200: 835-837.
50. Skowronski DM, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25: 2842-2851.
51. Tricco AC, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Medicine 2013; 11: 153.
52. Barr IG, et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014; 32: 4713-4725.
53. Regan A, et al. Electronic health record extraction from general practice for monitoring influenza vaccine coverage and effectiveness. Communicable Diseases Control Conference. Brisbane, Australia: Public Health Association of Australasia, 2015, pp. 52.
54. Fielding JE, et al. Estimation of type-and subtypespecific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008. BMC Infectious Diseases 2011; 11: 170.
55. Fielding JE, et al. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerging Infectious Diseases 2011; 17: 1181-1187.
56. Fielding JE, et al. Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Eurosurveillance 2012; 17: pii = 20115.
57. Skowronski D, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada s sentinel surveillance network, January 2013. Eurosurveillance 2013; 18: pii = 20394.
58. Skowronski D, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. Eurosurveillance 2014; 19.
59. Osterholm MT, et al. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases 2012; 12: 36-44.
60. Darvishian M, et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: A metaanalysis of test-negative design case-control studies. Lancet Infectious Diseases 2014; 14: 1228-1239.
61. Tamerius J, et al. Global influenza seasonality: reconciling patterns across temperate and tropical regions. Environmental Health Perspectives 2011; 119: 439-445.
62. Tamerius JD, et al. Environmental predictors of seasonal influenza epidemics across temperate and tropical climates. PLoS Pathogens 2013; 9: e1003194.
63. Koul PA, et al. Differences in influenza seasonality by latitude, northern India. Emerging Infectious Diseases 2014; 20: 1746-1749.
64. Australian Government Department of Health. Australian Influenza Surveillance Report. No. 8, 2014, 27 September to 10 October 2014. Canberra: Australian Government Department of Health, 2014.